Clinical significance of JNET classification and a proposal of countermeasure for issue of this classification

（JNET 分類の臨床的意義と課題解決策の提唱）

Kyoku Sumimoto
Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team

Kyoku Sumimoto, MD,1 Shinji Tanaka, MD, PhD,2 Kenjiro Shigita, MD,1 Daiki Hirano, MD,1 Yuzuru Tamaru, MD,1 Yuki Ninomiya, MD,1 Naoki Asayama, MD,1 Nana Hayashi, MD, PhD,2 Shiro Oka, MD, PhD,2 Koji Arihiro, MD, PhD,3 Masaharu Yoshihara, MD, PhD,4 Kazuaki Chayama, MD, PhD1 Hiroshima, Japan

Background and Aims: The Japan NBI Expert Team (JNET) was established in 2011 and has proposed a universal narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors. The aim of this study was to evaluate the clinical usefulness of the JNET classification for colorectal lesions.

Methods: We analyzed 2933 colorectal lesions, which were diagnosed by NBI magnifying observation before endoscopic treatment or surgery. The colorectal lesions consisted of 136 hyperplastic polyps/sessile serrated polyps (HPs/SSPs), 1926 low-grade dysplasia (LGD), 571 high-grade dysplasia (HGD), 87 superficial submucosal invasive (SM-s) carcinomas, and 213 deep submucosal invasive (SM-d) carcinomas. We evaluated the relationship between the JNET classification and the histologic findings of these lesions.

Results: The sensitivity, specificity, positive and negative predictive values, and accuracy of Type 1 lesions for the diagnosis of HP/SSP were, respectively, 87.5%, 99.9%, 97.5%, 99.4%, and 99.3%; of Type 2A lesions for the diagnosis of LGD were 74.3%, 92.7%, 98.3%, 38.7%, and 77.1%; of Type 2B lesions for the diagnosis of HGD/SM-s carcinoma were 61.9%, 82.8%, 50.9%, 88.2%, and 78.1%; for Type 3 lesions for the diagnosis of SM-d carcinoma were 55.4%, 99.8%, 95.2%, 96.6%, and 96.6%, respectively.

Conclusions: Types 1, 2A, and 3 of the JNET classification were very reliable indicators for HP/SSP, LGD, and SM-d carcinoma, respectively. However, the specificity and positive predictive value of Type 2B were relatively lower than those of others. Therefore, an additional examination such as pit pattern diagnosis using chromoagents is necessary for accurate diagnosis of Type 2B lesions. (Gastrointest Endosc 2017;85:816-21.)

Since the development of narrow-band imaging (NBI) in 1999, it has been a reliable tool that has contributed to improved diagnostic precision, such as detection of colorectal polyps,1-4 ulcerative colitis screening,5-7 differentiation of neoplastic lesions from non-neoplastic lesions, and characterization of colorectal neoplasia.8-14 Today, several colorectal NBI magnifying classifications, such as Hiroshima classification, Sano classification, Showa classification, and Jikei classification, are widely used and play a significant role clinically as well as pit pattern diagnosis.15,16 On the other hand, in Western countries, magnifying endoscopy is not commonly used in daily practice. The Colon Tumor NBI Interest Group proposed a new NBI classification called the NBI International Colorectal...
Endoscopic (NICE) classification in 2009,17 and validation studies were conducted in 2012.18,19 It is the first NBI classification that can be used both with and without magnifying endoscopy and has therefore spread all over the world.17,20 It is composed of 3 types that are divided according to color, vessels, and surface pattern. Type 1 is an indicator for hyperplastic polyp (HP), Type 5 is an indicator for deep submucosal invasive (SM-d) carcinoma, and Type 2 is an indicator for the other lesions of various histologic types, including low-grade dysplasia (LGD) to superficial submucosal invasive (SM-s) carcinoma (Table 1).19

The NICE classification is significantly useful because of its high diagnostic accuracy in detecting both non-neoplasia that does not need to be removed and SM-d carcinoma that needs to be resected by surgery.21,22 However, it is difficult to differentiate high-grade dysplasia (HGD) or SM-s carcinoma from LGD.17,23 This fact creates a clinical problem. We cannot determine the mode of endoscopic treatment, such as piecemeal endoscopic mucosal resection (EMR) or en bloc EMR/endoscopic submucosal dissection (ESD), for NICE Type 2 lesions because whether piecemeal EMR can be selected as a therapeutic method is based on the histologic characteristics of the lesions. If piecemeal EMR is not allowed for malignant lesions, to obtain a precise histologic diagnosis of a resected specimen we need to select ESD or surgery.15,23

To solve this issue, the Japanese NBI Expert Team (JNET) composed of Japanese magnifying colonoscopists was organized in 2011. Going through repeated detailed discussion and a web-based prospective trial, the JNET achieved consensus regarding NBI classification, and a new NBI colorectal magnifying classification (the JNET classification) was proposed in 2014.24 In this study we evaluated the clinical usefulness and problems of the JNET classification.

METHODS

In this study, NBI magnifying observation was performed at the Department of Endoscopy at Hiroshima University Hospital between January 2011 and March 2015. At this time 2933 consecutive cases of colorectal lesions, which had been endoscopically or surgically resected, were retrospectively analyzed. On the basis of histologic characteristics, 2933 lesions were identified as the following: HP/sessile serrated polyp (SSP) (136 lesions), LGD such as tubular adenoma/tubulovillous adenoma (1926 lesions), HGD (571 lesions), SM-s carcinoma less than 1000 μm (87 lesions), and SM-d carcinoma deeper than 1000 μm (213 lesions).

For these lesions, 3 colonoscopists with enough experience applied the JNET classification; the colorectal NBI magnifying classification consists of 4 types that are classified based on vessel pattern and surface pattern. The characteristics of Type 1 are invisible vessel pattern and having dark and white spots as surface pattern. The characteristics of Type 2A are regular vessel pattern, such as regular caliber or distribution, and regular surface pattern. The characteristics of Type 2B are irregular vessel pattern, such as variable caliber, irregular distribution, and irregular or obscure surface pattern. The characteristics of Type 3 are loose vessel areas or interruption of thick vessels and amorphous surface pattern (Fig. 1). These 3 colonoscopists were not involved in the endoscopic diagnosis of the lesions, and evaluation was performed objectively. In this process, the colonoscopists were blinded to all information concerning the endoscopic images and histopathologic findings.

The instrument used in this study was a magnifying videoendoscope system (CF-H260AZI; Olympus, Tokyo, Japan). The resected lesions were pathologically diagnosed in accordance with the criteria of the World Health Organization.25 One pathologist diagnosed all cases without any clinical information. Using these cases, we examined the relationship between each type of the JNET classification and histopathologic findings. The study protocol was approved by the Ethics Committee of Hiroshima University.

Statistical analysis

We calculated sensitivity, specificity, positive and negative predictive value (PPV and NPV), and accuracy for each category of the classification. The criterion standard for validation of predictions was the histology of colorectal lesions.

To calculate the interobserver agreement, we selected recent consecutive 1000 lesions. All 3 colonoscopists, who were blinded to all clinical information of lesions concerning endoscopic images and histopathologic findings, diagnosed NBI magnifying images simultaneously and recorded each JNET classification diagnosis. The interobserver agreement results based on the value of kappa statistics were defined as follows: poor, .2; fair, .21 to .4; moderate, .41 to .6; substantial, .61 to .8; and excellent, .81 to 1.

RESULTS

The relationship between NBI magnification findings and the histologic features of the colorectal lesions is shown in Table 2. Histologically, 98% (119/122) and 2% (3/122) of Type 1 lesions were identified as HP/SSP and LGD, respectively. In addition, 1% (17/1888), 86% (1626/1888), and 13% (245/1888) of Type 2A lesions were identified as HP/SSP, LGD, and HGD–SM-s carcinoma, respectively. Thirty-seven percent (297/799), 51% (407/799), and 12% (95/799) of Type 2B lesions were identified as LGD, HGD–SM-s carcinoma, and SM-d carcinoma, respectively. Five percent (5/124) and 95% (118/124) of Type 3 lesions were identified as HGD–SM-s carcinoma and SM-d carcinoma, respectively. The difference in the
percentage of HP/SSP versus LGD among Type 1 lesions was significant. The difference in the percentage of LGD versus HGD–SM-s carcinoma among Type 2A lesions was also significant, as was the difference in the percentage of SM-d carcinoma versus HGD–SM-s carcinoma among Type 3 lesions. However, the percentages of HGD–SM-s carcinoma and LGD among Type 2B were similar; both were nearly 40%.

The diagnostic characteristics of each category are shown in Table 3. The sensitivity, specificity, PPV, NPV,
and accuracy of Type 1 lesions for the diagnosis of HP/SSP were 87.5%, 99.9%, 97.5%, 99.4%, and 99.3%, respectively. The sensitivity, specificity, PPV, NPV, and accuracy of Type 2A lesions for the diagnosis of LGD were 74.3%, 92.7%, 98.3%, 38.7%, and 77.1%, respectively, and those of Type 2B lesions for the diagnosis of HGD–SM-s carcinoma were 61.9%, 82.8%, 50.9%, 88.2%, and 78.1%, respectively. Last, the sensitivity, specificity, PPV, NPV, and accuracy of Type 3 lesions for the diagnosis of SM-d carcinoma were 55.4%, 99.8%, 95.2%, 96.6%, and 96.6%, respectively. The overall interobserver agreement was good (κ = .749).

**DISCUSSION**

Removal of all adenomatous polyps has been standardized in Western countries because it can reduce colorectal cancer incidence and mortality.26,27 It is therefore routine
practice to retrieve polyps and collect them for pathologic evaluation. The interval of time to next surveillance colonoscopy can be only decided according to the final histologic diagnosis. The “Resect and Discard” policy has been advocated and states that an HP should be left in order to reduce the adverse events of polypectomy and cost of medical care. On the other hand, SM-d carcinoma is generally an indication for surgery because of its high risk of lymph node metastasis. The NICE classification is simple and very useful in identifying the lesions that do not need treatment and those that warrant surgery.

As reported previously, lesions showing NICE Type 2 include various lesions from LGD to SM-s carcinoma. Generally, piecemeal EMR can be allowed for benign adenoma. However, HGD–SM-s carcinoma should be completely resected by en bloc EMR or ESD to obtain a precise histologic diagnosis for judgment of curability, including the risk stratification of lymph node metastasis. Therefore, the diagnosis of NICE Type 2 is insufficient for the correct selection of a therapeutic method, such as piecemeal EMR or ESD.

To distinguish LGD from HGD–SM-s carcinoma, magnifying detailed observation is needed. To solve this problem and unify the various NBI classifications in Japan, the JNET was established in 2011, and a new NBI classification with magnification (the JNET classification) was proposed in 2015. The principles and characteristics of the JNET classification are as follows: (1) the use of magnification is essential and the base is the NICE classification; (2) in the JNET classification, NICE Type 2 is divided into 2 subtypes (2A and 2B) using magnifying findings; (3) because magnification does not need estimation of color, the JNET classification does not include the finding of color; and (4) basic findings are composed of both vessel pattern and surface pattern.

Our results in this study showed the sensitivity, specificity, PPV, NPV, and accuracy of each type for the most likely kind of histology found in the JNET classification. Types 1, 2A, and 3 have a specificity over 90% and a high PPV over 95%. This means that Types 1, 2A, and 3 of the JNET classification are definite indicators of their respective most likely histology, with significant diagnostic accuracy. On the other hand, the specificity of Type 2B was 82.8% and PPV of Type 2B was 50.9%, significantly lower than those of the others. Thus, the ability of Type 2B to identify HGD–SM-s carcinoma is not significant. This may be because of the variety of Type 2B lesions; Types 1, 2A, and 3 correspond to their respective most likely histology, which occupies more than 95% of each type (HP/SSP for Type 1, LGD for Type 2A, and SM-d carcinoma for Type 3). The lesions with irregular vessel and irregular surface patterns are classified as Type 2B, and show various histologic findings, ranging from LGD to SM-d carcinoma.

According to these results, in daily practice the JNET classification is useful for characterization of colorectal lesions of Types 1, 2A, and 3. Being different from detection of tumor in screening colonoscopy in which sensitivity is important, in the diagnosis before treatment the specificity of the classification is more reliable and important for determining the adequate treatment method for each lesion. On the other hand, lesions of Type 2B need an additional pit pattern diagnosis using magnification with chromoagents such as indigo carmine or crystal violet.

As reported previously, lesions showing NICE Type 2 include various lesions from LGD to SM-s carcinoma. Generally, piecemeal EMR can be allowed for benign adenoma. However, HGD–SM-s carcinoma should be completely resected by en bloc EMR or ESD to obtain a precise histologic diagnosis for judgment of curability, including the risk stratification of lymph node metastasis. Therefore, the diagnosis of NICE Type 2 is insufficient for the correct selection of a therapeutic method, such as piecemeal EMR or ESD.

To distinguish LGD from HGD–SM-s carcinoma, magnifying detailed observation is needed. To solve this problem and unify the various NBI classifications in Japan, the JNET was established in 2011, and a new NBI classification with magnification (the JNET classification) was proposed in 2015. The principles and characteristics of the JNET classification are as follows: (1) the use of magnification is essential and the base is the NICE classification; (2) in the JNET classification, NICE Type 2 is divided into 2 subtypes (2A and 2B) using magnifying findings; (3) because magnification does not need estimation of color, the JNET classification does not include the finding of color; and (4) basic findings are composed of both vessel pattern and surface pattern.

Our results in this study showed the sensitivity, specificity, PPV, NPV, and accuracy of each type for the most likely kind of histology found in the JNET classification. Types 1, 2A, and 3 have a specificity over 90% and a high PPV over 95%. This means that Types 1, 2A, and 3 of the JNET classification are definite indicators of their respective most likely histology, with significant diagnostic accuracy. On the other hand, the specificity of Type 2B was 82.8% and PPV of Type 2B was 50.9%, significantly lower than those of the others. Thus, the ability of Type 2B to identify HGD–SM-s carcinoma is not significant. This may be because of the variety of Type 2B lesions; Types 1, 2A, and 3 correspond to their respective most likely histology, which occupies more than 95% of each type (HP/SSP for Type 1, LGD for Type 2A, and SM-d carcinoma for Type 3). The lesions with irregular vessel and irregular surface patterns are classified as Type 2B, and show various histologic findings, ranging from LGD to SM-d carcinoma.

According to these results, in daily practice the JNET classification is useful for characterization of colorectal lesions of Types 1, 2A, and 3. Being different from detection of tumor in screening colonoscopy in which sensitivity is important, in the diagnosis before treatment the specificity of the classification is more reliable and important for determining the adequate treatment method for each lesion. On the other hand, lesions of Type 2B need an additional pit pattern diagnosis using magnification with chromoagents such as indigo carmine or crystal violet. Of course, even for the diagnosis of Types 1, 2A, and 3, if the confidence level is low, an additional pit pattern diagnosis using chromoagents should be applied (Fig. 2). At present, the optical zoom magnifying endoscope is not widely used in clinical practice in Western countries; however, recently the use of magnification has been increasing step by step all over the world. The Exela III and Lucera Elite systems (Olympus), recently developed videoendoscope systems and also used in Western countries, have a function of dual focus with electronic zoom, providing almost the same image of optical zoom magnifying images. Thus, magnification has gradually become common, and it is expected to become standard in the near future. Also, dye spray chromoendoscopy is expected to become common in relation to the spread of magnification.

Finally, the NICE classification has been used practically worldwide without requiring the technique of magnifying endoscopy because of its simplicity, convenience, high accuracy, and practical usefulness for diagnoses and decisions regarding treatment methods.

The recently proposed JNET classification is a unified, detailed Japanese magnifying NBI classification based on this NICE classification. In this study, we preliminarily examined the characteristics and pitfalls of the JNET classification. A detailed validation study of the JNET classification, including the diagnostic ability of the relationship with each NBI magnifying finding, is now ongoing by the JNET.

REFERENCES


Diagnostic performance of Japan NBI Expert Team classification for differentiation among noninvasive, superficially invasive, and deeply invasive colorectal neoplasia

Kyoku Sumimoto, MD,1 Shinji Tanaka, MD, PhD,2 Kenjiro Shigita, MD,1 Nana Hayashi, MD, PhD,2 Daiki Hiran0, MD,3 Yuzuru Tamaru, MD,1 Yuki Ninomiya, MD,1 Shiro Oka, MD, PhD,2 Koji Arihiro, MD, PhD,3 Fumio Shimamoto, MD, PhD,4 Masaharu Yoshihara, MD, PhD,5 Kazuaki Chayama, MD, PhD1

Hiroshima, Japan

Backgrounds and Aims: The Japan NBI Expert Team (JNET) classification is the first universal narrow-band imaging magnifying endoscopic classification of colorectal tumors. Considering each type in this classification, the diagnostic ability of Type 2B is the weakest. Generally, clinical behavior is believed to be different in each gross type of colorectal tumor. We evaluated the differences in the diagnostic performance of JNET classification for each gross type (polypoid and superficial) and examined whether the diagnostic performance of Type 2B could be improved by subtyping.

Methods: We analyzed 2933 consecutive cases of colorectal lesions, including 136 hyperplastic polyps/sessile serrated polyps, 1926 low-grade dysplasias (LGDs), 571 high-grade dysplasias (HGDs), and 300 submucosal (SM) carcinomas. We classified lesions as polypoid and superficial type and compared the diagnostic performance of the classification system in each type. Additionally, we subtyped Type 2B into 2B-low and 2B-high based on the level of irregularity in surface and vessel patterns, and we evaluated the relationship between the subtypes and histology, as analyzed separately for polypoid and superficial types. We also estimated interobserver and intraobserver variability.

Results: The diagnostic performance of JNET classification did not differ significantly between polypoid and superficial lesions. Ninety-nine percent of Type 2B-low lesions were LGDs, HGDs, or superficial submucosal invasive (SM-s) carcinomas. In contrast, 60% of Type 2B-high lesions were deep submucosal invasive (SM-d) carcinomas. The results were not different between each gross type. Interobserver and intraobserver agreements for Type 2B subtyping were good, with kappa values of .743 and .786, respectively.

Conclusions: Type 2B subtyping may be useful for identifying lesions that are appropriate for endoscopic resection. JNET classification and Type 2B sub classification are useful criteria, regardless of gross type. (Gastrointest Endosc 2017;86:700-9.)

Abbreviations: HGD, high-grade dysplasia; HP, hyperplastic polyp; JNET, Japan NBI Expert Team; LGD, low-grade dysplasia; NBI, narrow-band imaging; NICE classification, NBI International Colorectal Endoscopic classification; SM-d carcinoma, deep submucosal invasive carcinoma; SM-s carcinoma, superficial submucosal invasive carcinoma; SSP, sessile serrated polyp.

DISCLOSURE: All authors disclosed no financial relationships relevant to this publication. Research support for this study was provided to Shinji Tanaka by a Grant-in-Aid from the Japan Agency for Medical Research and Development, AMED (15ck0106102b0102).

Use your mobile device to scan this QR code and watch the author interview. Download a free QR code scanner by searching “QR Scanner” in your mobile device’s app store.
The narrow-band imaging (NBI) system has been used widely to diagnose GI neoplasia since it was first developed in 1999 in Japan. Many reports have confirmed that NBI observation is useful for detecting colorectal tumors, differentiating between neoplastic and non-neoplastic colorectal lesions, and diagnosing the invasive depth of colorectal carcinomas. As such, NBI classifications have become an important and necessary modality for daily colonoscopic examinations. In 2009, the Colon Tumor NBI Interest Group (CTNIG) proposed an NBI classification for colorectal tumors, the NBI International Colorectal Endoscopic (NICE) classification. NICE classification was the first classification for colon tumors that could be applied with or without magnifying observation. Because of its simplicity and usefulness, NICE classification spread rapidly in Western countries, where NBI magnification had not yet become common.

In Japan, many NBI magnifying classifications for colon tumors were used, such as Hiroshima classification, Sano classification, Showa classification, and Jikei classification, each used at different facilities. To unify the classifications, a committee of 38 magnifying colonoscopy specialists in Japan, the Japan NBI Expert Team (JNET), was organized in 2011. In 2014 JNET proposed the first unified colorectal NBI magnifying classification, the JNET classification. The JNET classification is composed of 4 types, types 1, 2A, 2B, and 3, and 2 NBI magnifying findings, surface pattern and vessel pattern. Types 1, 2A, 2B, and 3 are intended to indicate the most likely histology. Type 1 refers to hyperplastic polyps (HPs) and sessile serrated polyps (SSPs). Type 2A refers to low-grade dysplasias (LGDs), such as tubular adenomas or tubulovillous adenomas. Type 2B refers to high-grade dysplasias (HGDs) and superficial submucosal invasive (SM-s) carcinomas. Type 3 refers to deep submucosal invasive (SM-d) carcinomas. As we have previously reported, Types 1, 2A, and 3 are highly reliable indicators for their respective most likely histology, with significant qualitative and quantitative accuracy. On the other hand, the ability of Type 2B to indicate HGD and SM-s carcinoma is weaker than the abilities of the other 3 types, because Type 2B contains lesions with a variety of histology, ranging from LGD to SM-d carcinoma. A variety of gross types of colorectal tumors exhibit different clinical behaviors in terms of growth or invasion, differences in the diagnostic performance of the JNET classification have not been reported according to gross type. This study aimed to evaluate the diagnostic performance of the JNET classification for each gross type of lesion and to determine whether further subtyping of Type 2B could improve diagnostic performance.

METHODS

This study included 2933 consecutive cases of colorectal lesions that had been endoscopically or surgically resected. A total of 1901 patients were enrolled; 1351 patients (71.1%) had 1 lesion, 314 patients (16.5%) had 2 lesions, 132 patients (6.9%) had 3 lesions, and 104 patients (5.5%) had 4 or more lesions. All lesions were assumed to be independent observations for the purpose of statistical analysis. Each case was examined by NBI magnifying observation at the Department of Endoscopy of Hiroshima University Hospital between January 2011 and March 2015. Based on their histologic characteristics, 2933 lesions were identified as follows: 136 HP/SSP lesions, 1926 LGD lesions, 571 HGD lesions, 87 SM-s carcinoma lesions, and 213 SM-d carcinoma lesions. The mean diameters (standard deviations) of the HP/SSP, LGD, HGD, SM-s carcinoma, and SM-d carcinoma lesions were 8.9 (7.6) mm, 11.4 (10.7) mm, 25.7 (17.3) mm, 25.1 (13.9) mm, and 26.0 (14.3) mm, respectively.

The NBI criteria for each type from the JNET classification are described in Figure 1. Type 1 lesions are characterized by an invisible vessel pattern with dark and white spots as the surface pattern. Type 2A lesions are characterized by a regular vessel pattern, such as a regular caliber or distribution, and a regular surface pattern. Type 2B lesions are characterized by an irregular vessel pattern, such as a variable caliber or irregular distribution, with an irregular or obscure surface pattern. Type 3 lesions are characterized by loose vessel areas or interruption of thick vessels and an amorphous surface pattern.

First, we evaluated the diagnostic performance of each JNET type in terms of its ability to predict the most likely histology. To compare differences in diagnostic accuracy between each gross type, we classified the lesions as polypoid or superficial according to the Paris classification and then evaluated the diagnostic performance for each group. To evaluate the diagnostic ability as an indicator of the most likely histology, we calculated sensitivity, specificity, positive and negative predictive values, and accuracy for each type of JNET classification. Histologic findings of the colorectal lesions were used as the standard against which the optical predictions were validated.

Second, we subclassified 799 consecutive Type 2B lesions into 2B-low and 2B-high subtypes. We used blinded NBI magnifying endoscopic images to determine whether further subtyping of Type 2B could improve diagnostic performance.
results. Interobserver and intraobserver variabilities were estimated. The relationships between the Type 2B subtypes and histology results were also examined for each gross type.

To evaluate the NBI magnifying images, the lesions were diagnosed according to the JNET classification by 3 proficient endoscopists, each of whom had at least 5 years of experience using NBI. The endoscopists were blinded to all clinical information on the lesions that was related to the standard endoscopic images and histology results. They arrived at the diagnoses based on the NBI magnifying images alone. Interobserver variability for the Type 2B subtyping was analyzed for the 3 endoscopists and the kappa value calculated. Of the 799 cases that were diagnosed as Type 2B, the analysis of interobserver and intraobserver variability used the 216 consecutive cases that were detected by colonoscopy between January 2014 and November 2014. We used the NBI magnifying still images with 1 image per lesion. Two weeks after making the first diagnosis, and without undergoing any specific training for NBI diagnosis during that time, 1 of 3 participating endoscopists was presented with the NBI magnifying images from the same 216 cases in a different order. To analyze intraobserver variability, she then subclassified them again, while remaining blinded to the results from the first trial.

The colonoscope used in this study was a magnifying videoendoscope (CF-H260AZI and CF-HQ290ZI; Olympus Optical, Tokyo, Japan). The maximum magnification level in this study was approximately 70-fold for each scope. Histologic diagnosis was performed in accordance with the World Health Organization criteria by a pathologist (F. S.) who was blinded to the clinical information. The depth of SM invasion was defined according to the 2014 Japanese Society for Cancer of the Colon and Rectum guidelines for the treatment of colorectal cancer. This study was conducted with full approval from the Ethics Committee of Hiroshima University Hospital.

### Statistical analysis

The kappa values for interobserver and intraobserver agreement were interpreted as follows: poor, .00 to .20; fair, .21 to .40; moderate, .41 to .60; substantial, .61 to .80; and excellent, .81 to 1.00. Kappa values provide a measure of the agreement that is present, above and beyond that which would be expected from chance alone. A kappa value of 1.00 indicates perfect agreement, a value of .00 indicates no more agreement than would

---

**Figure 1.** The Japan NBI Expert Team classification (narrow-band imaging [NBI] magnifying classification for colorectal neoplasia).
be expected by chance alone, and a negative value indicates less agreement than would be expected from chance alone. Differences in nominal variables were analyzed using the Fisher exact test. \( P < .05 \) was considered statistically significant. JMP version 10.0 (SAS Institute, Cary, NC) was used for all statistical analysis. Although there was multiple testing of outcome data arising from individual lesions, no corrections to the \( P \) values were made because the purpose of the research was to highlight any potential differences.

**RESULTS**

**Relationships between the JNET classification and histologic findings for each gross type**

The results of NBI magnifying endoscopic diagnoses for all 2933 lesions using the JNET classification are shown in Table 1. According to the Paris classification, 2114 of the 2933 lesions were categorized as polypoid lesions (0-I\(s \) and 0-I\(p \)) and the remaining 819 as superficial lesions (0-II\(a \), 0-II\(b \), and 0-II\(c \)).

The 2114 polypoid-type lesions consisted of 57 HP/SSP lesions, 1435 LGD lesions, 431 HGD lesions, 50 SM-s carcinoma lesions, and 141 SM-d carcinoma lesions (Table 2). Histologically, 98\% (46/47) and 2\% (1/47) of Type 1 lesions were identified as HP/SSP and LGD, respectively. One percent (1/1,460), 86\% (1,253/1,460), and 14\% (196/1,460) of Type 2A lesions were identified as HP/SSP, LGD, and HGD/SM-s carcinoma, respectively. Thirty-four percent (181/531), 54\% (283/531), and 13\% (67/531) of Type 2B lesions were identified as LGD, HGD/SM-s carcinoma, and SM-d carcinoma, respectively. Three percent (2/76) and 97\% (74/76) of Type 3 lesions were identified as SM-s carcinoma and SM-d carcinoma, respectively.

The 819 superficial-type lesions consisted of 79 HP/SSP lesions, 491 LGD lesions, 140 HGD lesions, 37 SM-s carcinoma lesions, and 72 SM-d carcinoma lesions (Table 3). Histologically, 97\% (73/75) and 3\% (2/75) of Type 1 lesions were identified as HP/SSP and LGD, respectively. One percent (6/428), 87\% (373/428), and 12\% (49/428) of Type 2A lesions were identified as HP/SSP, LGD, and HGD/SM-s carcinoma, respectively. Forty-three percent (116/268), 47\% (124/268), and 10\% (28/268) of Type 2B lesions were identified as LGD, HGD/SM-s carcinoma, and SM-d carcinoma, respectively. Eight percent (4/48) and 92\% (44/48) of Type 3 lesions were identified as HGD/SM-s carcinoma and SM-d carcinoma, respectively. The relationships of the JNET classifications and their respective most likely histologic findings for both polypoid lesions and superficial lesions are shown in Table 4. No significant difference was observed for any types in the JNET classification (\( P > .5 \)).

**Performance characteristics of the JNET classification for each gross type**

The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Type 1 classification as a means of diagnosing HP/SSP were 80.7\%, 100.0\%, 97.9\%, 99.5\%, and 99.4\% for polypoid lesions and 92.4\%, 99.7\%, 97.3\%, 99.2\%, and 99.0\% for superficial lesions, respectively. The corresponding values for the
Type 2A classification as a means of diagnosing LGD were 77.0%, 90.7%, 98.4%, 34.4%, and 77.1% for polypoid lesions and 66.4%, 95.2%, 97.9%, 45.9%, and 73.0% for superficial lesions, respectively. Further, the corresponding values for the Type 2B classification as a means of diagnosing HGD or SM-s carcinoma were 58.8%, 84.8%, 53.3%, 87.5%, and 78.9% for polypoid lesions and 70.1%, 77.6%, 46.3%, 90.4%, and 76.0% for superficial lesions, respectively. Finally, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Type 3 categorization as a means of diagnosing SM-d carcinoma were 52.5%, 99.7%, 92.5%, 96.7%, and 96.5% for polypoid lesions and 61.1%, 99.5%, 91.7%, 96.4%, and 96.1% for superficial lesions, respectively (Table 5).

### Relationships between the JNET classification with Type 2B subtyping and histologic findings for all colorectal lesions

The 799 Type 2B lesions were subclassified into 656 Type 2B-low lesions and 143 Type 2B-high lesions (Table 6). Histologically, the 656 Type 2B-low lesions consisted of 297 LGDs (45%), 351 HGDs/SM-s carcinomas (54%), and 8 SM-d carcinomas (1%), whereas the 143 Type 2B-high lesions consisted of 56 HGDs/SM-s carcinomas (39%) and 87 SM-d carcinomas (61%).

---

**Table 1. The relationship between the JNET classification and histologic findings in colorectal lesion**

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>Histologic findings</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>LGD</td>
</tr>
<tr>
<td>Type 1</td>
<td>122 (100)</td>
<td>119 (98)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Type 2A</td>
<td>1888 (100)</td>
<td>17 (1)</td>
<td>1626 (86)</td>
</tr>
<tr>
<td>Type 2B</td>
<td>799 (100)</td>
<td>297 (37)</td>
<td>340 (43)</td>
</tr>
<tr>
<td>Type 3</td>
<td>124 (100)</td>
<td>1 (1)</td>
<td>5 (4)</td>
</tr>
<tr>
<td>Total</td>
<td>2933</td>
<td>136</td>
<td>1926</td>
</tr>
</tbody>
</table>

JNET, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).

**Table 2. Relationship between the JNET classification and histologic findings for polypoid colorectal lesion**

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>Histologic findings</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>LGD</td>
</tr>
<tr>
<td>Type 1</td>
<td>47 (100)</td>
<td>46 (98)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Type 2A</td>
<td>1460 (100)</td>
<td>11 (1)</td>
<td>1253 (86)</td>
</tr>
<tr>
<td>Type 2B</td>
<td>531 (100)</td>
<td>181 (34)</td>
<td>247 (47)</td>
</tr>
<tr>
<td>Type 3</td>
<td>76 (100)</td>
<td>2 (3)</td>
<td>74 (97)</td>
</tr>
<tr>
<td>Total</td>
<td>2114</td>
<td>57</td>
<td>1435</td>
</tr>
</tbody>
</table>

JNET, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).

**Table 3. Relationship between the JNET classification and histologic findings for superficial colorectal lesion**

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>Histologic findings</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>LGD</td>
</tr>
<tr>
<td>Type 1</td>
<td>75 (100)</td>
<td>73 (97)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Type 2A</td>
<td>428 (100)</td>
<td>6 (1)</td>
<td>373 (87)</td>
</tr>
<tr>
<td>Type 2B</td>
<td>268 (100)</td>
<td>116 (43)</td>
<td>93 (35)</td>
</tr>
<tr>
<td>Type 3</td>
<td>48 (100)</td>
<td>1 (2)</td>
<td>3 (6)</td>
</tr>
<tr>
<td>Total</td>
<td>819</td>
<td>79</td>
<td>491</td>
</tr>
</tbody>
</table>

JNET, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).
The overall interobserver agreement for Type 2B subtyping among the 3 endoscopists was good, with a kappa value of .743 (95% confidence interval, .671-.823). The intraobserver agreement was also good for the endoscopist who was evaluated, with a kappa value of .786 (95% confidence interval, .691-.884).

Relationships between the JNET classification with Type 2B subtyping and histologic findings for colorectal lesions of each gross type

Of the 799 Type 2B lesions, 531 were polypoid type and 268 were superficial type. The 531 polypoid lesions of Type 2B were subclassified into 437 Type 2B-low lesions and 94 Type 2B-high lesions (Table 7). Histologically, the 437 Type 2B-low lesions consisted of 181 LGDs (41%), 248 HGDs/SM-s carcinomas (57%), and 8 SM-d carcinomas (2%), whereas the 94 Type 2B-high lesions consisted of 35 HGDs/SM-s carcinomas (37%) and 59 SM-d carcinomas (63%). There was no significant difference in the relationship of Type 2B subtyping and histologic findings between polypoid lesions and superficial lesions, although a nearly significant difference

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>Gross type</th>
<th>Histologic findings (%)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>Non-HP/SSP</td>
</tr>
<tr>
<td>Type 1</td>
<td>Polypoid</td>
<td>46 (98)</td>
<td>1 (2)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>73 (97)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Type 2A</td>
<td>Polypoid</td>
<td>1253 (86)</td>
<td>207 (14)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>373 (87)</td>
<td>55 (13)</td>
</tr>
<tr>
<td>Type 2B</td>
<td>Polypoid</td>
<td>263 (54)</td>
<td>248 (46)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>124 (47)</td>
<td>144 (53)</td>
</tr>
<tr>
<td>Type 3</td>
<td>Polypoid</td>
<td>74 (97)</td>
<td>2 (3)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>44 (92)</td>
<td>4 (8)</td>
</tr>
</tbody>
</table>

*χ² test.

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>Gross type</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1</td>
<td>All</td>
<td>87.5 (81.9-93.1)</td>
<td>99.9 (99.8-100.0)</td>
<td>97.5 (94.8-100.3)</td>
<td>99.4 (99.1-99.7)</td>
<td>99.3 (99.0-99.6)</td>
</tr>
<tr>
<td></td>
<td>Polypoid</td>
<td>80.7 (70.5-90.9)</td>
<td>100.0 (99.9-100.0)</td>
<td>97.9 (93.7-102.0)</td>
<td>99.5 (99.2-99.8)</td>
<td>99.4 (99.1-99.8)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>92.4 (86.6-98.2)</td>
<td>99.7 (99.4-100.1)</td>
<td>97.3 (93.7-101.0)</td>
<td>99.2 (98.6-99.8)</td>
<td>99.0 (98.4-99.7)</td>
</tr>
<tr>
<td>Type 2A</td>
<td>All</td>
<td>74.3 (72.6-76.0)</td>
<td>92.7 (90.2-95.1)</td>
<td>98.3 (97.7-98.9)</td>
<td>38.7 (35.7-41.6)</td>
<td>77.1 (75.5-78.6)</td>
</tr>
<tr>
<td></td>
<td>Polypoid</td>
<td>77.0 (75.1-78.9)</td>
<td>90.7 (87.1-94.3)</td>
<td>98.4 (97.8-99.1)</td>
<td>34.4 (30.8-38.0)</td>
<td>77.1 (75.5-78.6)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>66.4 (62.7-70.1)</td>
<td>95.2 (92.2-98.3)</td>
<td>97.9 (96.5-99.3)</td>
<td>45.9 (41.0-50.9)</td>
<td>73.0 (70.0-76.1)</td>
</tr>
<tr>
<td>Type 2B</td>
<td>All</td>
<td>61.9 (58.1-65.6)</td>
<td>82.8 (81.2-84.3)</td>
<td>50.9 (47.5-54.4)</td>
<td>88.2 (86.9-89.6)</td>
<td>78.1 (76.6-79.6)</td>
</tr>
<tr>
<td></td>
<td>Polypoid</td>
<td>58.8 (54.4-63.2)</td>
<td>84.8 (83.1-86.6)</td>
<td>53.3 (49.1-57.5)</td>
<td>87.5 (85.9-89.1)</td>
<td>78.9 (77.2-80.6)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>70.1 (63.3-76.8)</td>
<td>77.6 (74.4-80.8)</td>
<td>46.3 (40.3-52.2)</td>
<td>90.4 (87.9-92.9)</td>
<td>76.0 (73.1-78.9)</td>
</tr>
<tr>
<td>Type 3</td>
<td>All</td>
<td>55.4 (48.7-62.1)</td>
<td>99.8 (99.6-100.0)</td>
<td>95.2 (91.4-98.9)</td>
<td>96.6 (95.9-97.3)</td>
<td>96.6 (95.9-97.2)</td>
</tr>
<tr>
<td></td>
<td>Polypoid</td>
<td>52.5 (44.2-60.7)</td>
<td>99.7 (99.5-99.9)</td>
<td>92.5 (86.7-98.3)</td>
<td>96.7 (95.9-97.5)</td>
<td>96.5 (95.8-97.3)</td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>61.1 (49.9-72.4)</td>
<td>99.5 (98.9-100.0)</td>
<td>91.7 (83.8-99.5)</td>
<td>96.4 (95.1-97.7)</td>
<td>96.1 (94.8-97.4)</td>
</tr>
</tbody>
</table>

Values are percents with 95% confidence intervals in parentheses.

JNET, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).
was observed for Type 2B-low lesions ($P = .0571$ for type 2B-low and $P = .589$ for type 2B-high; Table 9).

**DISCUSSION**

In general, there is a consensus in Japan that LGD, HGD, and SM-s carcinoma are considered to be appropriate for endoscopic resection.32,33 Additionally, SM-d carcinoma should be surgically resected because of the possibility of lymph node metastasis. As a principle, en bloc resection is essential for carcinoma to obtain a precise histologic diagnosis.33,34 Detailed histologic information can only be acquired from a complete specimen, and having this information enables us to make decisions regarding the curability and the necessity of additional surgical treatment in each case.35,36 Because HGD (which is generally regarded as an intramucosal carcinoma in Japan) can potentially invade the submucosal layer, both HGD and SM-s carcinoma require an en bloc resection technique, such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD).32,37,38 Unlike carcinoma, LGD can be treated not only using en bloc EMR or ESD but instead using piecemeal EMR to achieve a complete cure.32 For carcinoma within an adenomatous component, the cancerous area—if it can be detected in advance—should be carefully resected en bloc to obtain a precise histologic diagnosis, and fragmentation is allowed for the noncancerous area (this is so-called planned piecemeal EMR).39-42 Thus, the treatment methods that are adequate for each lesion differ based on their histologic features.33 In this way, a precise optical diagnosis before treatment is very important for selecting an adequate treatment procedure, such as piecemeal EMR, en bloc endoscopic resection (en bloc EMR/ESD), or surgery.43,44

Regarding the JNET Type 2B subtyping, about 80% of Type 2B lesions were classified as Type 2B-low. Further, the large majority of the Type 2B-low lesions were LGD, HGD, or SM-s carcinoma. Because almost all Type 2B-low lesions were LGD, HGD, or SM-s carcinoma, Type 2B-low can be regarded as a reliable indicator for endoscopic resection when examining the various histologic types of Type 2B cases. On the other hand, about 60% of Type 2B-high lesions were SM-d carcinoma, which requires surgery, whereas the remaining lesions were HGD or SM-s carcinoma. This finding suggests that Type 2B-high is not a reliable indicator for surgery. Thus, for Type 2B-low lesions, which comprise about 80% of Type 2B lesions, endoscopic treatment can be a first choice in the therapeutic strategy process. For Type 2B-high lesions, because they alone cannot be identified with SM-d carcinoma, further examination is necessary to differentiate HGD and SM-s carcinoma from SM-d carcinoma, thereby avoiding unnecessary surgery. To determine the appropriate treatment method (endoscopic resection or surgery) for Type 2B-high lesions, pit pattern diagnosis using chromoagents45,46 or endoscopic ultrasonography 47,48 is necessary to diagnose the correct invasion depth. However, no additional examination is necessary for Type 2B-low lesions.

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>Histologic findings</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>LGD</td>
</tr>
<tr>
<td>Type 2B-low</td>
<td>656 (100)</td>
<td></td>
<td>297 (45)</td>
</tr>
<tr>
<td>Type 2B-high</td>
<td>143 (100)</td>
<td></td>
<td>19 (13)</td>
</tr>
<tr>
<td>Total</td>
<td>799</td>
<td></td>
<td>297</td>
</tr>
</tbody>
</table>

*JNET*, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>Histologic findings</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HP/SSP</td>
<td>LGD</td>
</tr>
<tr>
<td>Type 2B-low</td>
<td>437 (100)</td>
<td></td>
<td>181 (41)</td>
</tr>
<tr>
<td>Type 2B-high</td>
<td>94 (100)</td>
<td></td>
<td>15 (16)</td>
</tr>
<tr>
<td>Total</td>
<td>531</td>
<td></td>
<td>181</td>
</tr>
</tbody>
</table>

*JNET*, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).
because most of these are appropriate for endoscopic resection (Fig. 3). The fact that nearly 80% of Type 2B lesions (subtyped in Type 2B-low) can be selected for the appropriate treatment method by NBI magnifying endoscopy alone provides simplicity, efficiency, and cost benefits for the management of Type 2B lesions in daily colonoscopic practice.

Regarding the variability of Type 2B subtyping, both interobserver and intraobserver agreements were good. Type 2B subtyping may be performed as easily as the JNET classification in clinical practice. Of course, if there is low confidence in the diagnosis for any lesion or if the lesion is difficult to subclassify into either Type 2B-low or 2B-high, then another examination should be performed in addition to NBI magnification to arrive at a diagnosis with high confidence.

The JNET classification is an NBI magnifying endoscopic classification of colorectal tumors, the essence of which was based on the NICE classification. JNET Type 1 and 3 correspond to NICE Type 1 and 3, respectively. Additionally, JNET Type 2A and 2B correspond to the NICE Type 2 subclassification.24 The findings of color that are used in the NICE classification are unnecessary for the JNET classification because magnification does not estimate color. Using fine NBI magnification, we have found it to be possible to differentiate LGD (JNET Type 2A) from HGD/SM-s carcinoma (JNET Type 2B), both of which had been classified as NICE Type 2 lesions. As we reported previously, JNET Type 1, 2A, and 3 are highly reliable indicators of HP/SSP, LGD, and SM-d carcinoma, respectively. On the other hand, the ability of JNET Type 2B as a means of diagnosing HGD and SM-s carcinoma is lower than the abilities of the other 3 types because of a variety of histologies.25 This is the reason we believed it was necessary to subtype Type 2B lesions, as a means of providing a more detailed optical diagnosis for these lesions.

In this study we also focused on the gross type of the lesions. Generally, colorectal tumors generally exhibit various gross types and growth patterns. The histologic characteristics and molecular biologic features are different for each gross type.26,27,49 Previously, we reported that the NBI magnifying findings differ according to growth pattern.50 In this study we estimated the diagnostic performance of the JNET classification for polypoid lesions and superficial lesions separately. As shown in Results, there was no significant difference in overall diagnostic accuracy between the gross types. The sensitivities of each type seem to be different between polypoid lesions and superficial lesions. Note that overall diagnostic accuracy is a weighted average of sensitivity and specificity, with weights determined by the relative proportions of true positives and true negatives. As shown in Table 4, the specificity is high and there are mostly true negatives. Accordingly, the level of sensitivity may play a small role in determining the value of overall diagnostic accuracy. We expected no significant difference in the characteristics of the Type 2B subtype between the gross types as well as the

### Table 8. Relationship between the JNET classification with subtyping of type 2B and histologic findings in superficial colorectal lesion

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>n, (%)</th>
<th>HP/SSP</th>
<th>LGD</th>
<th>HGD</th>
<th>SM-s</th>
<th>SM-d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2B-low</td>
<td>219 (100)</td>
<td>116 (53)</td>
<td>89 (41)</td>
<td>14 (6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2B-high</td>
<td>49 (100)</td>
<td>4 (8)</td>
<td>17 (35)</td>
<td>28 (57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>268</td>
<td>116</td>
<td>93</td>
<td>31</td>
<td>28</td>
<td></td>
</tr>
</tbody>
</table>

JNET, Japan NBI Expert Team; HP, hyperplastic lesion; SSP, sessile serrated polyp; LGD, low-grade dysplasia; HGD, high-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).

### Table 9. Relationship between the JNET classification with subtyping of Type 2B and histologic findings in polypoid type and superficial type

<table>
<thead>
<tr>
<th>JNET classification</th>
<th>Gross type</th>
<th>n (100)</th>
<th>Histologic findings</th>
<th>HP/SSP</th>
<th>LGD SM-s (%)</th>
<th>SM-d (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2B-low</td>
<td>Polypoid</td>
<td>437 (100)</td>
<td>429 (98)</td>
<td>8 (2)</td>
<td>.0571</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>219 (100)</td>
<td>219 (100)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2B-high</td>
<td>Polypoid</td>
<td>94 (100)</td>
<td>35 (37)</td>
<td>59 (63)</td>
<td>.5890</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Superficial</td>
<td>49 (100)</td>
<td>21 (43)</td>
<td>28 (57)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>799</td>
<td>704</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

JNET, Japan NBI Expert Team; LGD, low-grade dysplasia; SM-s, superficial submucosal invasive carcinoma (<1000 μm); SM-d, deep submucosal invasive carcinoma (≥1000 μm).
JNET classification. As shown in Table 9, the proportions of histologic findings for Type 2B-low lesions were almost significantly different between polypoid and superficial lesions, with a $P = .0571$. The reason for this near-statistically significant difference might be that no superficial SM-d carcinoma appeared to be JNET Type 2B-low. Generally, SM-d carcinomas correspond to JNET Type 3. Some advanced lesions of the polypoid type could have a slightly less irregular NBI appearance than Type 3 because the surface microvillous structure remains, which seldom happens to superficial advanced lesions. Thus, it can be suggested that the JNET classification, and also Type 2B subtyping, can be applied to high diagnostic accuracy for characterizing colorectal tumors (ie, as non-neoplasia vs dysplasia vs SM invasive carcinoma) for both polypoid lesion and superficial lesion.

In conclusion, regardless of the gross type, the JNET classification provides useful criteria for optical histologic diagnoses of colorectal lesions. Our proposal of Type 2B subtyping may improve the diagnostic performance of the JNET classification and contribute to daily coloscopic practice.

REFERENCES


